Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oct. 14 ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...

July 23, 2024 — Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP ... the development of new drugs to treat the disease, which ...

Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

The increasing incidence of sexually transmitted bacterial infections (STIs) is a major public health problem worldwide.

The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

(HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and ... Generic TDF/FTC reached the highest monthly share of users among all medications from December 2021 to December ...